- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
ABIOMED is a medical devices business based in the US. ABIOMED shares (ABMD) are listed on the NASDAQ and all prices are listed in US Dollars. ABIOMED employs 2,003 staff and has a trailing 12-month revenue of around $1.1 billion.
|Latest market close||$0.00|
|52-week range||$219.85 - $381.99|
|50-day moving average||$351.42|
|200-day moving average||$291.67|
|Wall St. target price||$363.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$5.83|
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2023-01-22)||nan%|
|1 month (2022-12-29)||nan%|
|3 months (2022-11-02)||-100.00%|
|6 months (2022-08-02)||-100.00%|
|1 year (2022-02-02)||-100.00%|
|2 years (2021-02-02)||-100.00%|
|3 years (2020-01-31)||186.29|
|5 years (2018-02-02)||248.2|
Valuing ABIOMED stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ABIOMED's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
ABIOMED's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 65x. In other words, ABIOMED shares trade at around 65x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
ABIOMED's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.75. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into ABIOMED's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
ABIOMED's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $274.2 million.
The EBITDA is a measure of a ABIOMED's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$1.1 billion|
|Operating margin TTM||22.96%|
|Gross profit TTM||$843.6 million|
|Return on assets TTM||9.55%|
|Return on equity TTM||18.24%|
|Market capitalisation||$17.2 billion|
TTM: trailing 12 months
We're not expecting ABIOMED to pay a dividend over the next 12 months.
ABIOMED's shares were split on a 2:1 basis on 1 October 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your ABIOMED shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for ABIOMED shares which in turn could have impacted ABIOMED's share price.
Over the last 12 months, ABIOMED's shares have ranged in value from as little as $219.85 up to $381.99. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ABIOMED's is 1.3976. This would suggest that ABIOMED's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2. 5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5. 0, Impella LD, and Impella 5.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.